9 Biosimilars for Intravitreal nAMD, DME Treatment

A number of biosimilar options to treat the common retina diseases are in development globally. Here’s a highlight of 9 with supporting late-stage data.

Related Keywords

South Korea ,P Biocon Biologics ,Aflibercept Eylea Biosimilars ,Chong Kun Dang ,Ranibizumab Lucentis Biosimilars ,Samsung Bioepis ,Momenta Pharmaceuticals ,Biocon Biologics ,Ophthalmology ,Biosimilars ,Biosimilar ,Retina ,Amd ,Dme ,Age Related Macular Degeneration ,Diabetic Macular Edema ,Drugs ,Anti Vegf ,Options ,